Naija Gist - Latest

Do hard things for the soft life, ALX celebrates Africa’s newest Data Scientists

On a day filled with high energy and excitement, ALX, Africa's leading tech career accelerator, proudly announces the successful graduation of over 2,000 learners from its yearly Data Science cohort.
Seeking Alpha

ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2 ...

Oral presentation at 2025 ASCO Gastrointestinal Cancers Symposium today highlights evorpacept as the first CD47 blocker to show substantial tumor response and a well-tolerated safety profile in a ...
Nasdaq

ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Robust Objective Response in Patients with Gastric or Gastroesophageal Junction Cancer

-- ORR of 72% Observed in Patients with >2L HER2 Positive Gastric or Gastroesophageal Junction Cancer -- Estimated OS at 12 months of 76% -- ALX Oncology to Host Conference Call on July 6th at 8:30 ...
Investing

ALX Oncology to present CD47 biomarker data for evorpacept at SITC

SOUTH SAN FRANCISCO - ALX Oncology Holdings Inc. (NASDAQ:ALXO), a clinical-stage biotechnology company with a market capitalization of $102 million, will present updated data from its Phase 2 ASPEN-06 ...
Nasdaq

ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2 ...

SOUTH SAN FRANCISCO, Calif., Jan. 23, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies ...